Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-TD: SD-809 for Tardive Dyskinesia
NCT02291861Phase 3Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of deutetrabenazine in tardive dyskinesia (TD) (4 arms), sponsored by Auspex Pharmaceuticals. Primary endpoint: Abnormal Involuntary Movement Scale at 12 weeks. Started Oct 2014; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT02291861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291861.